Wake Forest commercializes new soy technologies through licenses

March 21, 2002

WINSTON-SALEM, N.C. - Wake Forest University School of Medicine has licensed three soy-related technologies to Physicians Laboratories of Kernersville, which will use the technologies to develop "medical foods," according to Dean Stell, assistant director of technology asset management.

Aaron T. Tabor MD, president and medical director of Physicians Laboratories, said the company planned to start clinical trials soon on using soy to slow memory loss.

Medical foods, which are regulated by the U.S. Food and Drug Administration, are available only by prescription. If the medical benefits of a food can be demonstrated through clinical trials, then manufacturers are permitted to make medical claims. "If you have the evidence, you can say your product is for the nutritional management of memory disorders," Tabor explained.

The technologies were originally developed by Thomas B. Clarkson DVM, professor of pathology (comparative medicine) and other members of the Comparative Medicine Clinical Research Center based on 15 years of research on plant estrogens and more than 45 years of research on atherosclerosis.

Stell said that in addition to memory loss, the technologies also include using plant estrogens in hormone replacement therapy and in preventing endometriosis with plant estrogens.

Physicians Laboratories Inc. already markets soy protein on its web site under the Revival brand name as dietary supplements, which are not as heavily regulated as medical foods.

The initial study on soy and prevention of memory loss will be a pilot study involving 25-50 patients in nursing homes. "If the results are promising, we would look to expand that trial greatly through our own funding and government funding."

Tabor said his company was planning clinical trials for the other two technologies "We want to develop a product for the nutritional management of endometrioisis," he said. "That would be one of the claims we would hope to win for the second soy patent."

The third study will compare soy combined with hormone replacement therapy against hormone replacement therapy alone, with the goal of increasing bone density or lowering cholesterol.

"It's exciting for us to have some of our research findings be implemented into practice," said Clarkson. "I'm also excited by the scientific integrity by which Dr. Tabor has gone about implementing our research findings."

"This is what our office is all about," said Spencer Lemons, director of Technology Asset Management, "leveraging the research capabilities and expertise of the medical school with local, national and international companies to help create products that can potentially benefit the public."

"The fact that we can work with a local company in this instance, just makes it that much sweeter." Physicians Laboratories began about 3 1/2 years ago, and has grown to 90 employees and about $20 million a year in sales. The company markets soy under the Revival brand name, selling exclusively over the Internet and by telephone.

The company has focused on clinical trials, Tabor said, and has about ten under way. Meantime, the products are being sold as dietary supplements. Tabor said with dietary supplements, the company can make structure or function claims, such as soy promotes healthy cholesterol levels or soy lowers the risk of heart disease or soy promotes healthy memory but not treatment claims.. Tabor said the company would be working further with Clarkson's team on soy compounds that may lower the risk of breast cancer.
-end-
Contact: Robert Conn, (rconn@wfubmc.edu), Jim Steele (jsteele@wfubmc.edu) or Mark Wright (mwright@wfubmc.edu) at 336-716-4587

Wake Forest Baptist Medical Center

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.